Novel Halomethylketone Azadipeptides for Treating COVID-19

Page view(s)
393
Checked on Jun 17, 2024
Novel Halomethylketone Azadipeptides for Treating COVID-19
Title:
Novel Halomethylketone Azadipeptides for Treating COVID-19
Journal Title:
ACS Medicinal Chemistry Letters
Publication Date:
27 May 2022
Citation:
Chia, C. S. B., & See, Y. Y. (2022). Novel Halomethylketone Azadipeptides for Treating COVID-19. ACS Medicinal Chemistry Letters, 13(6), 875–876. https://doi.org/10.1021/acsmedchemlett.2c00136
Abstract:
COVID-19 is a highly infectious disease caused by the SARS-CoV-2 coronavirus. It rapidly escalated into a global pandemic, causing more than 6 million fatalities by March 2022, a little over 2 years since its emergence in December 2019. The first peptidomimetic coronavirus main protease inhibitor, nirmatrelvir, was granted Emergency Use Authorization by the U.S. FDA on Dec 22, 2021. Less than a month after its patent application, Hoffmann La-Roche scientists filed a patent application describing azadipeptide peptidomimetic inhibitors (WO 2022/043374 A1). This patent highlight reveals the structure–activity relationship of key azadipeptide inhibitors described in the patent.
License type:
Publisher Copyright
Funding Info:
This research is supported by core funding from: Experimental Drug Development Centre
Grant Reference no. : NRF2021-IE-IECF-001
Description:
This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Medicinal Chemistry Letters, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see /doi.org/10.1021/acsmedchemlett.2c00136
ISSN:
1948-5875
Files uploaded: